tbuckley/cabot-search huggingface dataset:
P247 CURBO2–65 is superior to CURB-65 in predicting readmissions, length of stay and identifying sicker patients: Abstract P247 Table 1.
Authors: C Molugu, W Falconer, A Singer, A Disney, P Stockton, L McCulloch, A Lewis, V Peers
Journal: Thorax (2013)

<h3>Introduction and Objectives</h3> Community Acquired Pneumonia (CAP) accounts for a significant proportion of hospital admissions and is a common cause of mortality and morbidity in UK. CURB-65 is recommended by BTS and widely used to stratify patients according to severity and guide initial treatment<b> (1)</b>. As oxygen is not part of the CURB-65 assessment, we incorporated Oxygen saturations (SATS) to CURB-65 to create CURBO2–65 score. We then compared CURBO2–65 with CURB65 to assess if CURBO2–65 would be a superior indicator in identifying patients with severe pneumonia. <h3>Methods</h3> We retrospectively reviewed electronic medical records of patients who were diagnosed with CAP between December 2012 and January 2013. CURB-65 was documented for all the cases whilst CURBO2–65 scores were retrospectively calculated. A score of 1 was allocated if SATS were &lt;88% for COPD patients or &lt;94% for non-COPD patients. A score of 1 was added if they were on supplemental Oxygen to maintain their SATS. <h3>Results</h3> (see Table 1) Total of 269 admissions with CAP were analysed. 12 of these 269 patients were admitted to critical care. 2/12 (ITU) patients had a CURBO2–65 score of ≤ 2 whilst 7/12 had a CURB-65 score ≤2. CURBO2–65 also had a better correlation with MEWS than CURB-65 on admission (p &lt; 0.05). Only 10% of cases with a CURBO2–65 score of 0–1 (5/50) were readmitted within 28 days compared to 15% of cases with a CURB-65 score 0–1 (13/87). There was a statistically significant correlation between length of stay and CURB-65 (p = 0.0085) and CURBO2–65 (p = 0.0014). <h3>Conclusions</h3> CURBO2–65 is superior to CURB-65 in identifying sicker cohort of patients, predicting readmission rates and length of stay. Adding Oxygen to CURB-65 is simple and can be undertaken even in primary care setting (CRBO2–65 instead of CRB-65). <h3>References</h3> <b>Lim WS <i>et al</i></b>. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. <i>Thorax</i> 2003;58:377–382.
<i>Chlamydia trachomatis</i>Infections in Female Military Recruits
Authors: Charlotte A. Gaydos, M. Rene Howell, Barbara Pare, Kathryn L. Clark, Dorothy A. Ellis, Rose Marie Hendrix, Joel C. Gaydos, Kelly T. McKee, Thomas C. Quinn
Journal: New England Journal of Medicine (1998)

Asymptomatic genital Chlamydia trachomatis infections in women can lead to pelvic inflammatory disease, infertility, and ectopic pregnancy. To design a chlamydia-control program, we conducted a large survey of women in the U.S. military.
The Stein–Leventhal Syndrome
Authors: Irving F. Stein
Journal: New England Journal of Medicine (1958)

THE subject of the Stein–Leventhal syndrome in relation to sterility first aroused my curiosity about thirty years ago. I observed (with Leventhal1) a small group of women complaining of long periods of amenorrhea, sterility and hirsutism. In some of these women, one or both ovaries were palpably enlarged.Since we had been utilizing Peterson's technic of x-ray visualization of the pelvic viscera in controversial gynecologic disorders since 1923,2 we applied pneumoroentgenography (a form of gynecography3) to this group. We consistently found a striking picture of bilateral, symmetrically enlarged ovaries. We were curious to ascertain whether biopsy of the . . .
Abstract 2744: Loss of VAV3 expression as a novel biomarker and indicator of chemosensitivity in basal-like breast cancer
Authors: Julie E. Getz, Eric M. Anderson, Michael A. Black, Ingrid A. Hedenfalk, Yoganand Balagurunathan, Amanda L. Willis, Catherine M. Mancini, Pilar Ramos, Heather E. Cunliffe
Journal: Cancer Research (2010)

Abstract Microarray-based technologies have revealed at least five molecularly distinct subtypes of breast cancer that share similarities in their underlying disease biology and have more predictable responses to therapy: Luminal A, Luminal B, Basal-like, ERBB2 positive, and Normal Breast-like. The ability to objectively subclassify breast tumors adds significant prognostic information that is independent of standard clinical parameters and provides insight for clinical decision-making. Basal-like breast (BLB) cancer, accounts for approximately 16% of breast tumors diagnosed. The majority of BLB tumors do not express estrogen and progesterone receptors (ER/PR) and HER2/neu, and they commonly have mutations in the TP53 or BRCA1 genes. Patients diagnosed with BLB tumors have a relatively poor prognosis, and the molecular basis for disease progression in this subtype remains unclear. Due to proposed differences in etiology and mesenchymal characteristics of BLB tumors, we hypothesized that regulators of cell morphology, contractility and motility may be distinctly deregulated in this subtype and may provide insight into molecular pathology operating in BLB tumors. We therefore investigated genes associated with the Rho/Rac/Cdc42 superfamily, a key regulator of cell morphology. Using unsupervised hierarchical clustering, we confirmed diverse regulation of this gene superfamily in publicly available breast tumor gene expression microarray datasets. Very low expression of VAV3 was observed in BLB tumors compared to all other intrinsic subtypes across six breast cancer cohorts. Analysis of VAV3 transcript and protein expression in cell lines and tumor samples indicated low VAV3 expression correlates with BLB subtypes. We have confirmed that loss of VAV3 expression in BLB cell lines is not due to gene copy number loss by Fluorescence In Situ Hybridization and array Comparative Genomic Hybridization (aCGH). Kaplan Meyer analysis from publicly available breast tumor data suggested that elevated VAV3 expression in BLB tumors is predictive of response to chemotherapy. We are currently investigating whether exogenous VAV3 overexpression in BLB cancer cell lines increases their chemosensitivity. In conclusion, our findings support a hypothesis that VAV3 is a potential biomarker of BLB cancer, and VAV3 expression in BLB tumors may be a predictor of response to chemotherapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2744.
O6.03 * A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION AND RADIO-CHEMOTHERAPY FOLLOWING FLUORESCENCE-GUIDED SURGERY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS: PRELIMINARY CLINICAL RESULTS OF THE &lt;&lt;DEND/GBM&gt;&gt; TRIAL
Authors: J. Gallego Perez-Larraya, S. Tejada-Solis, A. L. de Cerio, S. Inoges, J. Espinos, R. Diez-Valle
Journal: Neuro-Oncology (2014)

BACKGROUND: Immunotherapy is emerging as a promising therapeutic modality for the treatment of glioblastoma (GBM). Recent clinical trials have supported the use of different therapeutic vaccines for high-grade gliomas, demonstrating promising feasibility and safety data. However, the wide variety of approaches and the limitations characterizing most studies preclude firm conclusions regarding efficacy. A phase II trial evaluating the efficacy and safety of autologous dendritic cells vaccination in addition to fluorescence-guided surgery and standard radio-chemotherapy with temozolomide in patients with newly diagnosed GBM was undertaken. PATIENTS AND METHODS: All consecutive patients aged 18 to 70 years who were candidates for resection of a suspected GBM were screened. An attempt at maximum resection was made in every case using fluorescence-guided surgery with 5-aminolevulinic acid. Less than 1 cc of residual tumour and histological confirmation of GBM were required for definite inclusion in the trial. Vaccines were prepared with autologous dendritic cells pulsed with tumour lysate and matured ex vivo. Vaccination calendar started before radiotherapy. Patients also received standard treatment consistent on radiotherapy with concomitant and up to 12 cycles of adjuvant temozolomide. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), safety, quality of life, and immune response. RESULTS: Thirty-two patients were screened between February 2009 and December 2011. One patient was excluded because of insufficient tumour resection (>1 cc of residual tumour). The mean age of the 31 included patients was 59 years. Median Karnofsky Performance Score (KPS) was 80% (range 60-100%). According to recursive partitioning analysis (RPA), 10% of the patients were RPA class III, 42% were class IV and 48% were class V. O6-methylguanine-DNA methyltransferase (MGMT) promoter was found to be unmethylated in 53% of the patients. Enough tumor lysate and dendritic cells were available in all cases to produce at least 6 vaccine doses. The median number of available vaccine doses was 11,2 (range, 6 to 17). Median PFS was 8.0 months and median OS was 27.4 months (95% CI: 20.9-33.0 months). No severe adverse events attributable to immunotherapy were identified. CONCLUSION: These results suggest that autologous dendritic cells vaccination is feasible and safe, and that the addition of this immunotherapy modality to gross total resection and standard radio-chemotherapy appears to increase survival in patients with newly diagnosed GBM.
Abstract LB-326: Synergistic therapeutic effects of cytokine-induced killer (CIK) cell and temozolomide against glioblastoma
Authors: Younggeon Jin, Juyoun Jin, Kyeung Min Joo, Se Jeong Lee, Mi-young Jo, Yonghyun Kim, Do-Hyun Nam
Journal: Cancer Research (2010)

Abstract The presence of active immunity within the brain supports the possibility of effective immunotherapy for glioblastoma (GBM). To provide a clinically-relevant adoptive immunotherapy for GBM using ex vivo expanded cytokine-induced killer (CIK) cells, the treatment capability of CIK cells, either alone or in combination with temozolomide (TMZ) were evaluated. Human CIK (hCIK) cells were cultured from PBMC using activating anti-CD3 antibody and IL-2, which were 99% CD3+, 91% CD3+CD8+ and 29% CD3+CD56+. In vitro, hCIK cells showed tumor-specific cytotoxicity against U-87MG human GBM cells. When hCIK cells were injected into tail veins of immune-compromised mice bearing U-87MG tumors in their brains, numerous CIK cells infiltrated into the brain tumors. CIK treatments (1 × 105, 1 × 106 or 1 × 107, once a week for four weeks) inhibited the tumor growth significantly in a dose-dependent manner; 44%, 54% and 72% tumor volume reduction, respectively, compared with the control group (P &amp;lt; 0.05). Moreover, hCIK cells (1 × 107, once a week for four weeks) and TMZ (2.5 mg/kg, daily for 5 days) combination treatment further increased tumor cell apoptosis and decreased tumor cell proliferation and vessel density (P &amp;lt; 0.05), creating a more potent therapeutic effect (95% reduction in tumor volume) compared with either hCIK cells or TMZ single therapy (72% for both, P &amp;lt; 0.05). Taken together, CIK cell-immunotherapy and TMZ chemotherapy have synergistic therapeutic effects and could be combined for a successful treatment of GBM. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-326.
SAT0409 Multidisciplinary Care in the Management of Fibromyalgia: A Randomized Controlled Trial
Authors: A. Abou-Raya, S. Abou-Raya, R. Faiez
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Chronic musculoskeletal pain disorders such as fibromyalgia (FM) have an impact on all aspects of well-being. <h3>Objectives</h3> To evaluate the effectiveness of a multidisciplinary care setting for the management of FM in comparison to standard care. <h3>Methods</h3> 82 FM patients (72 females, 10 males), mean age 49.9 years diagnosed according to the American College of Rheumatology (ACR) criteria for FM were randomized into one of 2 groups for 4 months therapy. The intervention group (n = 42) were assigned to a rheumatologist and a physiotherapist and were put on a 4-month structured exercise therapy programme, provision of stress and pain management and education on proper diet. The control group consisted of standard care with a general practitioner. Outcome measures included the Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Beck Depression Inventory (BDI), Visual analogue scale for pain (VAS 0-100mm) and Survey Short Form-36 (SF-36) assessment. All measures were assessed at baseline and after 4 months. There were no statistical differences between the 2 groups at baseline. <h3>Results</h3> The intervention group achieved statistically significant improvements in FIQ (p&lt; 0.01), BPI (p &lt;0.05), BDI (p, 0.05), VAS for pain (p&lt; 0.01) and physical functioning, bodily pain and mental health subscales of SF-36. There was a significant reduction in prescription drugs in the intervention group compared to the control standard care group, p &lt; 0.01. <h3>Conclusions</h3> Improvement in health-related outcomes in FM, a mostly difficult to treat often unresponsive condition may be achieved in a multidisciplinary care setting. <h3>Disclosure of Interest</h3> None Declared
Abstract 338: Truncating TP53 mutations have prognostic significance in head and neck squamous cell carcinoma
Authors: Marlon van der Plas, Ruud H. Brakenhoff, Dirk J. Kuik, Marijke Buijze, Elisabeth Bloemena, Peter Jf Snijders, C. René Leemans, Boudewijn Jm Braakhuis
Journal: Cancer Research (2011)

Abstract Background: TP53 is a key gene in cellular homeostasis and is frequently mutated in head and neck squamous cell carcinoma (HNSCC). There is a variety of TP53 mutations, each with its own biological and clinical implication. Some HNSCC are TP53 wild type, amongst those caused by infection with the human papillomavirus (HPV). Aim of the study was to assess the prognostic significance of TP53 mutations in HNSCC and to identify the most relevant mutation. Methods: TP53 mutation status was assessed by direct sequencing in 141 consecutive HNSCC treated by surgery with radiotherapy when indicated and with a known HPV-status. The type of mutation was correlated with overall survival in a multivariate two-sided Cox regression analysis with wild type as reference. Results: HPV infections was found in 12 out of 141 cases (9%). Although a relation between HPV infection and a favorable prognosis was observed, the association was not significant. A TP53 mutation was found in 88 (62.4%) of the carcinomas and was not associated with survival. Tumors with a mutation resulting in a truncated protein (n=36, 25.5% consisting of nonsense, frame shift and splice site mutations), had a significantly worse overall survival (Hazard ratio: 2.54 with 95% confidence intervals of 1.28 and 5.05, p=0.008). Multivariate analysis showed that a truncating mutation is an independent risk factor, adjusted for HPV status. A missense (i.e. non-truncating) mutation did not influence prognosis. Other ways of mutation classification (disruptive vs. non-disruptive, hotspot vs. non-hotspot and DNA-binding vs. non-DNA-binding) were less discriminative and co-factors, including HPV-status were confounding in these associations. Conclusion: Truncating mutations in the TP53 gene are an important independent predictor for a poor prognosis of HNSCC patients. This patient group is an ideal target population for adjuvant therapy with chemoradiation or viral vector mediated TP53 gene transfer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 338. doi:10.1158/1538-7445.AM2011-338
Abstract 2893: Integrated genomic meta-analysis of colorectal cancer by elastic-net.
Authors: HoJoon Lee, Patrick Flaherty, Hanlee P. Ji
Journal: Cancer Research (2013)

Abstract To identify combinatorial sets of known, putative and new cancer drivers responsible for colorectal cancer (CRC) development and other associated specific clinical outcomes, we have developed an integrative analysis method for cancer genome data. This approach is based on the elastic-net algorithm that we have applied to genomic data from the Cancer Genome Atlas (TCGA) Project. Our supervised analysis simultaneously assesses the contribution of i) copy number variation (CNV), ii) gene expression, iii) miRNA, iv) methylation and v) cancer mutations to clinical features. The ongoing TCGA project is generating genomic and clinical data sets from different tumor types including CRC. These detailed catalogues of genetic changes in cancer genomes will continue to provide us with new insights about cancer development. However, extracting biologically/clinically relevant information from TCGA's diverse and large cancer genome data remains a challenge. In attempt to overcome this challenge, we use regularized regression method: elastic-net that improves on “the least absolute shrinkage and selection operator” (Lasso). To demonstrate the performance and validity of this approach, we showed that elastic-net successfully identified i) synthetic genes that have their CNVs perfectly associated with stages from a simulated data ii) TGFBR2 and other driver genes that have mutations associated with CRCs that demonstrate microsatellite instability CRC from TCGA data, and iii) IDH1 that obtained mutations associated with survival according to glioblastoma (GBM) data. In the next phase of the study, we identified the top ranked genes that delineate key clinical features such as TNM stages of CRC. We have identified a series of candidate genes that may indicate clinical stages including novel candidates on chromosome 8. Overall, we have successfully demonstrated that our approach allows for an integrative and highly robust supervised analysis of TCGA data. Citation Format: HoJoon Lee, Patrick Flaherty, Hanlee P. Ji. Integrated genomic meta-analysis of colorectal cancer by elastic-net. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2893. doi:10.1158/1538-7445.AM2013-2893
Romney lays down pro-life credentials with vow to ban most abortions
Authors: J. H. Tanne
Journal: BMJ (2012)

Mitt Romney, the Republican candidate for US president, is backing a reversal of the ruling issued by the US Supreme Court in 1973 that made abortion legal and has said that he will ban the use of federal funds for abortions at home and abroad should he win the election.

In a letter posted on a pro-life news website, Romney spelt out in detail his present anti-abortion position, which is in contrast to his previous position when he was governor of Massachusetts.1 The letter is similar to the position outlined on Romney’s campaign website.2

In the letter Romney wrote, “I am firmly pro-life. I believe that if abortion were limited …
THU0055 Interstitial pneumonitis associated with rheumatoid arthritis is more prevalent in aged male with a higher RF level, and frequently combined with emphysema
Authors: E. Matsubara, S. Okiyama, S. Inokuma, K. Onishi, S. Nakachi, H. Asashima, K. Wakabayashi, K. Hagiwara, S. Kobayashi
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Previously well-known "rheumatoid-lung" has been assumed as interstitial pneumonitis (IP). It is not so prevalent in female-majority of rheumatoid arthritis (RA) patients, but rather observed much more in male patients. We have had an impression that IP in male RA patients has a unique feature of concurrent emphysema development. <h3>Objectives</h3> To study how frequently, and which pulmonary diseases develop in male RA patients. The background and associated laboratory features were also focused on. <h3>Methods</h3> Male RA patients who visited our hospital from Jan., 2006 to Apr., 2011 are included. The similar number of female patients visited us in the same duration was included as the controls. Lung diseases were diagnosed mainly based on the medical records, XP/HRCT findings, and pulmonary function tests results. As the major disease entities, usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), organizing pneumonia (OP), emphysema and pleuritis were intended. Brinkman Index (BI, smoking index), and serum levels of RF, KL-6 and CRP were evaluated. <h3>Results</h3> Lung diseases were observed in 27/72 (37.5%) in male and 5/70 (7.1%) in female patients. In male patients, UIP/NSIP was in 20, OP in 3, emphysema in 18, and pleuritis in 1; 12 had both IP and emphysema. In female, UIP was in 2, OP in 2, emphysema in 1, and pleuritis in 1; 1 had both IP and emphysema. The male patients with lung diseases were older than those without them (72.2±10.3 vs. 63.7±12.9 yr.), had a higher serum RF level (511±390 vs.140±141 U/mL), a higher KL-6 level (801±735 vs. 277±179 U/mL), and a higher Brinkman index. Among the cases with stable arthritis, patients with UIP/NSIP/emphysema showed a low CRP level, while those with OP/pleuritis did a high level. <h3>Conclusions</h3> Male RA patients had lung diseases at a high rate of over 30%. UIP/NSIP was observed the most, which was frequently combined with emphysema. The male RA patients having a high RF level and a high smoking index might develop UIP/NSIP and the combined emphysema with a high prevalence rate. Such patients showed a high KL-6 level but a low CRP level. <h3>Disclosure of Interest</h3> None Declared
P765Diabetic cardiomyopathy: a comparative investigation in diabetic rat models
Authors: C Matyas, S Korkmaz, A Olah, BT Nemeth, L Hidi, E Birtalan, M Torok, B Merkely, G Szabo, T Radovits
Journal: Cardiovascular Research (2014)

Purpose: Diabetic cardiomyopathy, a cardiac manifestation of diabetes mellitus (DM), is characterised by specific structural, molecular and functional alterations of the myocardium. Upon this concept we investigated whether type-1 or type-2 diabetes lead to different alterations in cardiac function or histological and molecular changes. Methods: Our experiments were carried out in a rat model of type-1 (streptozotocin induced) and type-2 DM (Zucker Diabetic Fatty rats). Left ventricular (LV) function was characterised using a pressure-volume (P-V) conductance catheter system. Load independent indices of LV contractility (preload recruitable stroke work (PRSW)) and indices of LV relaxation (time constant of LV pressure decay(Tau)) and stiffness (LV end-diastolic pressure (LVEDP)) were calculated, respectively. In addition to our functional measurements TUNEL assay was performed to evaluate degree of apoptosis. Myocardial gene expression analysis was performed by qRT-PCR, expression of proteins was investigated by western blot and immunohistochemistry. Results: In comparison to the control, type-1 DM resulted in decreased LV systolic performance: decreased systolic pressure, maximal dP/dt and PRSW (45.39±2.45 vs 76.44±4.06 mmHg). Type-2 DM was associated with increased LV stiffness (LVEDP: 9.4±0.5 vs 7.7±0.4 mmHg) while systolic indices were altered only to a lower extent. We observed cardiac hypertrophy and degeneration with histomorphological examination. More pronounced nitro-oxidative stress resulted in more severe DNA-damage. Overexpression of c-fos and c-jun and downregulation of eNOS were observed in type-1 diabetic rats. On the other hand TGF-β1 and ANF mRNA-levels were significantly higher in type-2 diabetic model. Conclusions: Diabetic cardiac alterations are characterised by decreased systolic performance and impaired relaxation in type-1 diabetic rats, while diastolic dysfunction was more pronounced in type-2 DM. In the background of diabetic cardiomyopathy different processes can be identified in the two models.